Log in
Enquire now
TG Therapeutics

TG Therapeutics

A biopharmaceutical company developing treatments for B-cell malignancies and autoimmune diseases

OverviewStructured DataIssuesContributors

Contents

tgtherapeutics.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Autoimmune disease
Autoimmune disease
0
Therapeutics
Therapeutics
Biopharmaceutical
Biopharmaceutical
Immunotherapy
Immunotherapy
Therapy
Therapy
Biomedical engineering
Biomedical engineering
Technology
Technology
...
Location
New York
New York
Morrisville, North Carolina
Morrisville, North Carolina
0
New York City
New York City
‌
New York, Iowa
United States
United States
B2X
B2B
B2B
CEO
Michael Weiss
Michael Weiss
0
Founder
Michael Weiss
Michael Weiss
0
AngelList URL
angel.co/tg-therapeutics0
Pitchbook URL
pitchbook.com/profiles...118863-46
Legal Name
TG Therapeutics, Inc.
Legal classification
Public company
Public company
0
Date Incorporated
May 18, 1993
Number of Employees (Ranges)
201 – 5000
Email Address
ir@tgtxinc.com0
clinicalsupport@tgtxinc.com0
media@tgtxinc.com0
med.info@tgtxinc.com0
Phone Number
+187784897770
+187784894620
+187757584990
Number of Employees
2190
Full Address
New York, NY 10014, US0
3020 Carrington Mill Blvd. Suite 475 Morrisville, NC 27560-54350
CIK Number
1,001,316
Place of Incorporation
Delaware
Delaware
IRS Number
363,898,269
Founded Date
2011
0
Total Funding Amount (USD)
25,000,000
Latest Funding Round Date
February 29, 2012
Competitors
Adagio Therapeutics
Adagio Therapeutics
Stock Symbol
TGTX
Exchange
Nasdaq
Nasdaq
0
Board of Directors
Daniel Hume
Daniel Hume
0
Sagar Lonial
Sagar Lonial
0
Kenneth Hoberman
Kenneth Hoberman
0
Yann Echelard
Yann Echelard
0
‌
Laurence N. Charney
0
CFO
Sean A. Power
Sean A. Power
0
Key People
Michael Weiss
Michael Weiss
Sean A. Power
Sean A. Power
Latest Funding Type
Series A
Series A
NAICS Code
325,4120
Wellfound ID
tg-therapeutics0
Country
United States
United States
Headquarters
New York
New York

Other attributes

Company Operating Status
Active
Previous Name
ATLANTIC PHARMACEUTICALS INC0
MANHATTAN PHARMACEUTICALS INC0
ATLANTIC TECHNOLOGY VENTURES INC0
Public/Private
Public0
SIC Code
2,834
Ticker Symbol
TGTX0
Wikidata ID
Q106301317

TG Therapeutics is a publicly owned biopharmaceutical company headquartered in New York City, New York that was founded in 1993 by Michael Sean Weiss and Laurence H. Shaw. It focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company's product pipeline has two therapies in clinical development, TG-1101 and TG-1202.

Products
TG-1101

TG-1101, also known as Ublituximab, is a monoclonal antibody that targets a specific epitope on the B-lymphocyte CD20 antigen. It has been bioengineered to deliver enhanced clinical activity and potency. The product is aimed at treating B-cell proliferative disorders including, Non-Hodgkin's Lymphoma (NHL) and Cronic Lymphocytic Leukemia (CLL). It has also shown effectiveness against autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), as well as the neurological disorder, Multiple Sclerosis (MS). Ublituximab is in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.

TG-1202

TG-1202, also known as Umbrasilib, is an orally available PI3K delta inhibitor. It targets delta isoforms, which is believed to be important in the proliferation and survival of B-cell lymphocytes. Umbrasilib is in Phase 3 clinical development in combination with Ublituximab for patients with hematological malignancies.

TG-1801 is the first treatment that targets both CD19 and CD47. CD19 is a B cell-specific marker widely expressed in B cell malignant tumors, while CD47 is expressed in both healthy and tumor cells, transmitting the "don't eat me" signal. In order to escape macrophage-mediated phagocytosis, CD47 is widely expressed in normal cells, including red blood cells and platelets. Co-targeting CD47 and CD19,TG-1801 has the potential to overcome the limitations of existing CD47 targeting therapy and avoid the side effects of indiscriminate blocking of CD47 on healthy cells.

TG has two therapies into III clinical development: (1) ublituximab, a new type of glycosylated anti-CD20 monoclonal antibody, Targeting specific epitopes of CD20 antigen on mature B lymphocytes; (2) umbralisib, an oral, daily, new generation of PI3K δ inhibitors, can uniquely inhibit CK1- ε, which may enable it to overcome some tolerance problems associated with the first generation of PI3K δ inhibitors.

The combination of ublituximab, umbralisib and U2 is in the clinical stage of III in the treatment of hematological malignant tumors, in addition, the treatment of multiple sclerosis with ublituximab has also been in the clinical stage of III. Just recently, the company pushed its anti-PD-1 monoclonal antibody TG-1501, a covalently bound BTK inhibitor TG-1701, into Phase I clinical practice.

Preclinical studies

TG Therapeutics has several other products in its pipeline, which are at various stages of preclinical studies:

IRAK4

A key signaling kinase that becomes inappropriately activated in tumors that carry certain oncogenic mutations of MYD88, which can be found in most patients with Waldensrom's Macroglobulinemia, a rare B-cell cancer, as well as in some specific cases of Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. IRAK4 is also key in regulating immune and inflammatory processes, suggesting that it may be useful in treating autoimmune related disorders.

Anti-PD-L1 & Anti-GITR

Anti-PD-L1 antibodies target programmed cell death ligand 1 (PD-L1). They are designed to block signals permitting effector T-cells to attack cancer. Anti-GITR antibodies target glucocorticoid-induced tumor necrosis factor receptor related protein (GITR). It has shown to amplify the antitumor immune responses in animal models. Pre-clinical research on therapies using a combination of these two antibodies have yielded positive results. The Anti-PD-L1 monoclonal antibody has been brought into Phase 1 of clinical development.

TG-1601

TG-1601 is a small molecule that binds to the epigenetic BET family of bromodomain-containing proteins and inhibits their binding to chromatin. It can increase the sensitivity of tumors to chemotherapy or specific standard of care by resetting the genome in tumor cells. TG-1601 is in pre-clinical development and is being tested in various IND-enabling studies.

TG-1701

TG-1701 is an orally available BTK inhibitor. Targeting BTk with small molecule inhibitors has demonstrated effectiveness as a treatment option for B-cell lymphomas and autoimmune diseases. The product is in Phase 1 clinical trials in China.

TG-1801

TG-1801 is the first treatment that targets both CD19 and CD47. CD19 is a B cell-specific marker widely expressed in B cell malignant tumors, while CD47 is expressed in both healthy and tumor cells, transmitting the "don't eat me" signal. In order to escape macrophage-mediated phagocytosis, CD47 is widely expressed in normal cells, including red blood cells and platelets. Co-targeting CD47 and CD19, TG-1801 has the potential to overcome the limitations of existing CD47 targeting therapy and avoid the side effects of indiscriminate blocking of CD47 on healthy cells.

TG has two therapies into III clinical development: (1) ublituximab, a new type of glycosylated anti-CD20 monoclonal antibody, Targeting specific epitopes of CD20 antigen on mature B lymphocytes; (2) umbralisib, an oral, daily, new generation of PI3K δ inhibitors, can uniquely inhibit CK1- ε, which may enable it to overcome some tolerance problems associated with the first generation of PI3K δ inhibitors.

The combination of ublituximab, umbralisib and U2 is in the clinical stage of III in the treatment of hematological malignant tumors, in addition, the treatment of multiple sclerosis with ublituximab has also been in the clinical stage of III. Just recently, the company pushed its anti-PD-1 monoclonal antibody TG-1501, a covalently bound BTK inhibitor TG-1701, into Phase I clinical practice.

Funding
Post-IPO Equity

On February 29, 2012 TG Therapeutics announced raising $25 million in Post-IPO capital.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

TG Therapeutics, Inc. Announces Oral Presentation of Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's Transformation at 60th American Society of Hematology Annual Meeting and Exposition

TG Therapeutics, Inc.

https://globenewswire.com/news-release/2018/12/03/1660702/0/en/TG-Therapeutics-Inc-Announces-Oral-Presentation-of-Follow-Up-Data-from-the-Triple-Combination-of-Ublituximab-Umbralisib-and-Pembrolizumab-in-Patients-with-Relapsed-Refractory-CLL-a.html

Web

References

Find more companies like TG Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.